• In early May 2026, Praxis Precision Medicines reported a first-quarter net loss of US$92.56 million, while also securing FDA acceptance of new drug applications for ulixacaltamide in essential tremor and relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies.
• Alongside these filings, Praxis highlighted positive early-stage data for elsunersen showing a very large placebo-adjusted seizure reduction in SCN2A-DEE, underscoring growing clinical momentum across its central nervous system pipeline.
• With the FDA now reviewing ulixacaltamide and relutrigine, we’ll explore how this regulatory progress may reshape Praxis Precision Medicines’ investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Praxis Precision Medicines Investment Narrative Recap

To own Praxis Precision Medicines, you need to believe that its late stage CNS portfolio, led by vormatrigine, relutrigine and ulixacaltamide, can translate clinical data into real world adoption before cash runs tight. Right now, the key near term catalyst is the upcoming POWER1 readout for vormatrigine, while the biggest risk is that any stumble in this or the other planned trials undercuts the value of a business still posting sizeable net losses.

Among the latest updates, the FDA’s acceptance of the NDAs for ulixacaltamide in essential tremor and relutrigine in SCN2A and SCN8A DEEs looks most relevant, because it moves Praxis from a pure development story toward potential commercial stage status at the same time that POWER1 and EMERALD data are pending. This combination of regulatory review and approaching readouts frames how much is at stake over the next few quarters.

Yet against all this momentum, investors should still be aware that the company remains loss making and heavily dependent on a handful of late stage assets...

Praxis Precision Medicines' narrative projects $724.1 million revenue and $89.5 million earnings by 2029. This requires 359.5% yearly revenue growth and a $362.5 million earnings increase from $-273.0 million today.

Uncover how Praxis Precision Medicines' forecasts yield a $449.13 fair value, a 36% upside to its current price.

Exploring Other Perspectives

Some of the most cautious analysts were assuming revenue of only about US$76.6 million by 2028 and ongoing losses, so if you are weighing today’s NDA acceptances and early elsunersen data, it is worth recognising how sharply their risk view contrasts with more optimistic takes and considering how these new developments might shift those expectations.

Explore 4 other fair value estimates on Praxis Precision Medicines - why the stock might be worth less than half the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Praxis Precision Medicines research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Praxis Precision Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Praxis Precision Medicines' overall financial health at a glance.

Curious About Other Options?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.